```html

Wegener’s Granulomatosis (Granulomatosis with Polyangiitis)

Overview

Wegener’s granulomatosis, now more commonly called Granulomatosis with Polyangiitis (GPA), is a rare, chronic autoimmune disease that causes inflammation of small‑ and medium‑sized blood vessels (vasculitis). The inflammation damages the walls of arteries and veins, leading to tissue injury in the respiratory tract (nose, sinuses, lungs) and the kidneys, and sometimes in the skin, eyes, ears, and nervous system.

• Who it affects: Adults between 40–60 years old are most commonly diagnosed, but GPA can occur at any age, including in children.
• Gender distribution: Slight male predominance (≈55 % men).
• Prevalence: Estimated 3–4 cases per 100,000 population in the United States and Europe [1][2].
• Geography: Similar incidence worldwide; no strong ethnic predilection.

Symptoms

Symptoms reflect the organs involved and may appear gradually over weeks to months. Early recognition is critical because untreated GPA can progress rapidly.

Upper Respiratory Tract

• Chronic sinusitis – nasal congestion, facial pain, post‑nasal drip.
• Nasal crusting or ulceration – may cause bloody discharge.
• Saddle‑nose deformity – collapse of the nasal bridge from cartilage loss.
• Ear problems – hearing loss, otitis media, or vertigo.

Lower Respiratory Tract

• Cough – dry or productive.
• Hemoptysis – coughing up blood, often a red‑flag symptom.
• Shortness of breath – due to lung nodules, infiltrates, or hemorrhage.
• Chest pain – pleuritic pain from lung inflammation.

Kidneys

• Hematuria – blood in urine, often microscopic.
• Proteinuria – foamy urine indicating protein loss.
• Rapidly progressive glomerulonephritis – can lead to kidney failure if untreated.

Systemic / Other Organ Involvement

• Fever, fatigue, weight loss – nonspecific but common.
• Joint pain – arthralgias without swelling.
• Skin lesions – palpable purpura, ulcers, or necrotic nodules.
• Eye involvement – redness, pain, scleritis, or vision changes.
• Neurologic symptoms – peripheral neuropathy, mononeuritis multiplex.

Causes and Risk Factors

The exact cause of GPA is unknown, but research points to a combination of genetic susceptibility and environmental triggers that lead to an abnormal immune response.

Immunologic Mechanism

• Autoantibodies called anti‑proteinase 3 antineutrophil cytoplasmic antibodies (PR3‑ANCA) are present in ~80 % of patients and are thought to activate neutrophils, causing vessel damage.

Genetic Factors

• Certain HLA genes (e.g., HLA‑DPB1*04) increase risk, though they account for only a modest portion of susceptibility.

Environmental Triggers

• Exposure to silica dust, farming chemicals, or chronic nasal infections has been linked to a higher incidence, but data are associative rather than causal.

Who Is at Higher Risk?

• Adults aged 40–60.
• Individuals with a family history of autoimmune disease.
• People with occupational exposure to silica or certain hydrocarbons.

Diagnosis

Because GPA mimics infections, malignancies, and other vasculitides, a systematic approach is essential.

Clinical Evaluation

• Detailed medical history and physical examination focusing on ENT, pulmonary, renal, and skin findings.

Laboratory Tests

• ANCA testing – PR3‑ANCA (c‑ANCA) is positive in ~80 % of active GPA; MPO‑ANCA (p‑ANCA) may be present in a minority.
• Complete blood count (CBC) – anemia, leukocytosis.
• Renal panel – creatinine, eGFR, urinalysis for hematuria/proteinuria.
• Inflammatory markers – ESR, CRP (usually elevated).

Imaging

• Chest X‑ray or CT scan – identifies nodules, cavitations, infiltrates, or alveolar hemorrhage.
• Sinus CT – shows mucosal thickening, bony erosion.

Biopsy (Gold Standard)

• Histologic confirmation of necrotizing granulomatous inflammation and vasculitis from affected tissue (e.g., nasal mucosa, lung, kidney).
• Kidney biopsy is often performed when glomerulonephritis is suspected.

Classification Criteria

The 2022 ACR/EULAR classification criteria for GPA require a combination of clinical features, ANCA status, and biopsy results, providing a standardized diagnostic framework (Mayo Clinic [3]).

Treatment Options

Therapy aims to induce remission, then maintain it while minimizing drug toxicity. Treatment is usually coordinated by a rheumatologist, nephrologist, and pulmonologist.

Induction Therapy (Rapid disease control)

• Corticosteroids – high‑dose oral prednisone (1 mg/kg/day) or IV methylprednisolone pulses (500–1000 mg/day for 3 days) until symptoms improve.
• Immunosuppressive agents (choose one):
  • Rituximab – anti‑CD20 monoclonal antibody (375 mg/m² weekly ×4 or 1 g on days 1 & 15). Shown to be non‑inferior to cyclophosphamide and preferred in patients with renal involvement or fertility concerns [4].
  • Cyclophosphamide – oral (2 mg/kg/day) or IV pulse (15 mg/kg every 2–3 weeks). Effective but carries risks of infertility, bladder toxicity, and secondary malignancy.
• Adjunctive plasmapheresis may be considered in severe renal disease or diffuse alveolar hemorrhage (KDIGO guidelines [5]).

Maintenance Therapy (Prevent relapse)

• Rituximab – 500 mg every 6 months for 2–4 years.
• Azathioprine – 2–2.5 mg/kg/day.
• Mycophenolate mofetil – 1–1.5 g twice daily (alternative for patients intolerant to azathioprine).
• Low‑dose prednisone (≤5 mg/day) is usually tapered after 6–12 months.

Supportive Care & Lifestyle Adjustments

• Vaccinations: pneumococcal, influenza, and COVID‑19 (preferably before starting immunosuppression).
• Bone health: calcium + vitamin D supplementation; bisphosphonate if long‑term steroids are needed.
• Infection prophylaxis: trimethoprim‑sulfamethoxazole for PCP (Pneumocystis) prevention during high‑dose immunosuppression.
• Smoking cessation – reduces pulmonary complications.
• Regular monitoring of blood counts, liver/kidney function, and ANCA titers.

Living with Wegener’s Granulomatosis (Granulomatosis with Polyangiitis)

Although GPA is chronic, many patients achieve long‑term remission and lead active lives.

Daily Management Tips

• Medication adherence – use a pill organizer or smartphone reminders.
• Track symptoms – keep a diary of respiratory, urinary, and constitutional changes; share with your care team.
• Regular labs – schedule blood work every 1–3 months during induction, then every 3–6 months for maintenance.
• Protect your lungs – avoid exposure to dust, fumes, and extreme temperatures; wear masks when exposure is unavoidable.
• Skin care – moisturize to prevent fissures; promptly treat any sores to avoid infection.
• Dental hygiene – periodontal disease can exacerbate sinus inflammation; brush twice daily and see a dentist regularly.
• Emotional health – chronic illness can be stressful; consider counseling, support groups, or online communities such as the Vasculitis Foundation.

Follow‑up Schedule

Visit Type	Frequency	Focus
Rheumatology	Every 1–2 months (induction) → Every 3–6 months (maintenance)	Disease activity, drug side effects, ANCA titers.
Nephrology	Every 3–6 months or as indicated	Kidney function, urine analysis.
Pulmonology	Annually or when respiratory symptoms change	CT chest, pulmonary function tests.

Prevention

Because GPA’s cause is not fully understood, primary prevention is limited. However, risk reduction strategies focus on mitigating triggers and early detection.

• Minimize occupational exposure to silica, dust, and chemicals.
• Maintain up‑to‑date vaccinations to reduce infection‑related immune activation.
• Promptly treat chronic sinus infections; consider referral to ENT if symptoms persist.
• Educate family members about warning signs so that early medical attention can be sought.

Complications

If left untreated or poorly controlled, GPA can cause irreversible organ damage.

• Renal failure – up to 50 % develop end‑stage kidney disease requiring dialysis or transplant.
• Permanent lung damage – fibrosis, bronchiectasis, or chronic pulmonary hemorrhage.
• Neuropathy – sensory or motor deficits may become permanent.
• Vision loss – scleritis or orbital granulomas can threaten sight.
• Cardiovascular disease – vasculitis of coronary vessels increases myocardial infarction risk.
• Medication toxicity – cyclophosphamide‑related bladder cancer, steroid‑induced osteoporosis, or rituximab infusion reactions.

When to Seek Emergency Care

---

Sources:

1. Hayden, M. et al. “Epidemiology of Granulomatosis with Polyangiitis.” Mayo Clinic Proceedings, 2020.
2. Waltenberger, J. “Incidence and prevalence of ANCA-associated vasculitis.” Ann Rheum Dis, 2021.
3. 2019 ACR/EULAR Classification Criteria for GPA. American College of Rheumatology.
4. Stone, J.H. et al. “Rituximab versus cyclophosphamide for ANCA‑associated vasculitis.” NEJM, 2010.
5. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl, 2022.
6. Vasculitis Foundation. “Living with GPA,” 2023. vasculitisfoundation.org.

```